Ferric carboxymaltose

Generic Name: Ferric carboxymaltose

Brand Names: Injectafer

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9007-72-1

Unique Ingredient Identifier: 6897GXD6OE

Background: Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.

Indication: Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy. It is also indicated in adult patients who have non-dialysis-dependent chronic kidney disease.

Associated Conditions: Iron Deficiency Anemia (IDA)

Associated Therapies: -

Clinical Trials

Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial

Phase 3

Conditions: Iron Deficiency Anemia
Inflammatory Bowel Diseases

Interventions: Drug: Sucrosomial iron
Drug: Ferric carboxymaltose
Drug: Ferric Gluconate

First Posted Date: 2020-10-14

Last Posted Date: 2020-10-19

Lead Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

Target Recruit Count: 300

Registration Number: NCT04587141

Locations: 🇮🇹
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation

Phase 4

Conditions: Blood Loss
Liver Transplantation

Interventions: Drug: Placebo
Drug: Iron Carboxymaltose

First Posted Date: 2020-07-17

Last Posted Date: 2020-07-28

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 60

Registration Number: NCT04475887

Locations: 🇦🇹
Medical University of Vienna, Department of Surgery, Vienna, Austria

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferric carboxymaltose

First Posted Date: 2020-02-17

Last Posted Date: 2022-03-21

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 7

Registration Number: NCT04269707

Locations: 🇺🇸
South Florida Research Phase I-IV, Miami Springs, Florida, United States
🇺🇸
Miami Clinical Research, Miami, Florida, United States

Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer

Phase 4

Not yet recruiting

Conditions: Anemia
Surgery
Gastric Cancer
Iron Deficiency Anemia
Surgery--Complications

Interventions: Drug: Placebos
Drug: Ferric carboxymaltose

First Posted Date: 2019-11-19

Last Posted Date: 2019-11-19

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 202

Registration Number: NCT04168346

Polyglucoferron Compared to i.v. Ferric Carboxymaltose and Oral Iron Substitution in Preoperative Treatment of Iron Deficiency Anaemia in Patients

Phase 3

Withdrawn

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferrous Sulfate
Drug: Polyglucoferron
Drug: Ferric carboxymaltose

First Posted Date: 2019-09-12

Last Posted Date: 2024-08-28

Lead Sponsor: Dr. Frank Behrens

Registration Number: NCT04087993

Locations: 🇩🇪
Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital of Goethe-University, Frankfurt, Hessia, Germany

Intraoperative IV Iron on Postoperative Red Blood Cell Recovery

Phase 4

Conditions: Osteoarthritis, Hip

Interventions: Drug: control
Drug: Ferric carboxymaltose

First Posted Date: 2019-07-29

Last Posted Date: 2020-08-19

Lead Sponsor: Konkuk University Medical Center

Target Recruit Count: 46

Registration Number: NCT04035902

Iron in Patients With Cardiovascular Disease

Phase 3

Terminated

Conditions: Atrial Fibrillation
Cardiovascular Diseases
Anemia, Iron-deficiency
Acute Myocardial Infarction
Systolic Heart Failure

Interventions: Drug: Ferric carboxymaltose
Drug: Saline

First Posted Date: 2019-06-19

Last Posted Date: 2023-12-27

Lead Sponsor: Dr. med. Mahir Karakas

Target Recruit Count: 8

Registration Number: NCT03991000

Locations: 🇩🇪
University of Ulm, Ulm, Germany
🇩🇪
University of Berlin, Campus Benjamin-Franklin, Berlin, Germany
🇩🇪
University Heart Center Hamburg, Hamburg, Germany

Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia

Phase 3

Completed

Conditions: Iron-deficiency
Postpartum Anemia Nos

Interventions: Drug: Iron Isomaltoside
Drug: Ferrous sulphate
Drug: Iron Carboxymaltose

First Posted Date: 2019-05-21

Last Posted Date: 2022-06-27

Lead Sponsor: University Medical Centre Ljubljana

Target Recruit Count: 300

Registration Number: NCT03957057

Locations: 🇸🇮
UMC Ljubljana, Ljubljana, Slovenia

Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure

Phase 4

Conditions: Systolic Heart Failure
Cardiac Failure
Heart Failure, Systolic

Interventions: Drug: Ferric carboxymaltose

First Posted Date: 2019-03-12

Last Posted Date: 2019-07-12

Lead Sponsor: Hospital Moinhos de Vento

Target Recruit Count: 20

Registration Number: NCT03871699

Locations: 🇧🇷
Hospital Moinhos de Vento, Porto Alegre, RS, Brazil

Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)

Phase 3

Conditions: Ferropenic Anemia
Heart Failure With Normal Ejection Fraction

Interventions: Drug: Ferroglycine Sulfate
Other: Placebo
Drug: Sucrosomial Iron
Drug: Ferric carboxymaltose

First Posted Date: 2019-02-07

Last Posted Date: 2019-02-08

Lead Sponsor: Institut de Recerca Biomèdica de Lleida

Target Recruit Count: 72

Registration Number: NCT03833336

Locations: 🇪🇸
Hospital Universitari Arnau de Vilanova, Lleida, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy